The developer, manufacturer, and marketer of orthopedic products for domestic and international markets lost its former CEO, Dan Goldberger, earlier this month after the chief executive resigned to "pursue other interests." The company did not elaborate on Goldberger's reason(s) for leaving the firm.
Xtant Medical President Carl O’Connell will serve as interim CEO while the company’s Board of Directors decides on Goldberger's replacement. O’Connell joined Xtant Medical in October 2016. He has previously worked in leadership roles at Wright Medical Group N.V., Calmare Therapeutics Inc. (formerly known as Competitive Technologies), the US Healthcare Division MedSurg for ITOCHU, Stryker Spine, and Carl Zeiss Surgical.
“We are thankful for Dan’s significant contributions to the company during his tenure as chief executive. Under Dan’s leadership, the company has made significant progress toward our strategic goals,” said Kent Swanson, board chairman. “We are fortunate to have Carl O’Connell agree to serve as interim CEO. Carl is an accomplished senior executive with a demonstrated history of leading marketing and sales organizations and deep healthcare and medical device experience. We look forward to working with Carl as we embark on the next phase of the company’s growth.”
Xtant Medical Holdings develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for treating spinal disease, tissue grafts for treating orthopedic disorders, and biologics to promote healing after cranial and foot and ankle surgeries.